NCT07700875 QR-12000 Essential Hypertension Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Move from a broad hypertension map to a decision-ready protocol. This report examines NCT07700875—A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026.
Why NCT07700875 is a hot trial to watch
NCT07700875 tests QR-12000 in moderate-to-severe essential hypertension, a field where differentiation depends on magnitude of blood-pressure reduction, durability, tolerability and activity in difficult-to-control populations. The asset is indexed at Phase 3 globally with AT2R × CD10 target context, while this protocol is a Phase 2 study.
Trial landscape table
| Field | Indexed detail |
|---|---|
| Registration | NCT07700875 |
| Official title | A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension |
| Phase / status | Phase 2 / Completed |
| Intervention | QR-12000 |
| Sponsor | Wuhan Createrna Science and Technology Co.,Ltd. |
| Geography | China |
| Enrollment | 391 |
| Primary endpoint | Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Week 8 |
| Endpoint time frame | Baseline and week 8. |
| Primary completion / readout proxy | 2023-08-20 |
Design and endpoint interpretation
Allocation is Randomized, masking is Quadruple, and the intervention model is Parallel Assignment. The primary endpoint—Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Week 8—should be interpreted with baseline blood pressure, ambulatory versus office measurement, background therapy, adherence and missing-data handling.
Benchmark readout context
Hypertension benchmarks should separate absolute systolic and diastolic change, responder thresholds, ambulatory blood-pressure effects, subgroup consistency and discontinuation due to adverse events. Cross-trial comparisons require alignment on baseline risk, run-in design and permitted rescue therapy.
Build a living monitor: connect to PatSnap MCP Servers to track amendments, completion dates and indexed results.
Asset and sponsor context
Drug & Asset context: QR-12000 is indexed at Phase 3 with AT2R × CD10 target context.
Company & Deal Intelligence context: Wuhan Createrna Science and Technology Co.,Ltd. — https://www.createrna.com/.
Sponsor capability matters because formulation, manufacturing, site reach and confirmatory funding influence whether a blood-pressure signal becomes a competitive asset.
White space
- Resistant-hypertension positioning: evidence in patients uncontrolled on contemporary combinations.
- Ambulatory confirmation: 24-hour coverage and nighttime effects.
- Safety differentiation: renal, electrolyte, orthostatic and adherence outcomes.
- Combination evidence: sequencing with renin-angiotensin, calcium-channel and diuretic therapy.
- External validity: broader geographic and demographic representation.
What to monitor next
Monitor recruitment, dose selection, endpoint hierarchy, ambulatory monitoring, primary-completion timing, first result indexing and sponsor partnerships.
Bottom line
NCT07700875 is a concrete Phase 2 lens on QR-12000 in essential hypertension. Its value will depend on clinically meaningful, durable blood-pressure control with a differentiated safety and adherence profile.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence.
